Therapeutic eradication choices in Helicobacter pylori infection in children

被引:0
作者
Manfredi, Marco [5 ]
Gargano, Giancarlo [1 ]
Gismondi, Pierpacifico [2 ]
Ferrari, Bernardino [3 ]
Iuliano, Silvia [4 ]
机构
[1] ASMN Hosp, Maternal & Child Dept, Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy
[2] Azienda Osped Univ Parma, Week Hosp Unit, Pietro Barilla Childrens Hosp, Dept Pediat, Parma, Italy
[3] ASST Franciacorta, Publ Hosp, Pediat Unit, Brescia, Italy
[4] Azienda Osped Univ Parma, Pietro Barilla Childrens Hosp, Dept Pediat, Pediat Gastroenterol, Parma, Italy
[5] Sant Anna Hosp, Maternal & Child Dept, Chief Pediat Unit, Azienda USL IRCCS Reggio Emilia, Via Roma 2, I-42035 Reggio Emilia, Italy
关键词
adjuvants; children; combination therapy; eradication treatment; Helicobacter pylori; susceptibility testing;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Current recommendations on Helicobacter pylori (H. pylori) eradication in children differ from adults. In H. pylori-infected adults, the eradication is always recommended because of the risk to develop gastrointestinal and non-gastrointestinal associated diseases. Instead, before treating infected children, we should consider all the possible causes and not merely focus on H. pylori infection. Indeed, pediatric international guidelines do not recommend the test and treat strategy in children. Therefore, gastroscopy with antimicrobial susceptibility testing by culture on gastric biopsies should be performed before starting the eradication therapy in children to better evaluate all the possible causes of the symptomatology and to increase the eradication rate. Whether antibiotic susceptibility testing is not available, gastroscopy is anyway recommended to better set any possible cause of symptoms and not simply focus on the presence of H. pylori. In children the lower antibiotics availability compared to adults forces to treat based on antimicrobial susceptibility testing to minimize the unsuccessful rates. The main antibiotics used in children are amoxicillin, clarithromycin, and metronidazole in various combinations. In empirical treatment, triple therapy for 14 days based either on local antimicrobial susceptibility or on personal antibiotic history is generally recommended. Triple therapy with high dose of amoxicillin is a valid alternative choice, either in double resistance or in second-line treatment. Moving from therapeutic regimens used in adults, we could also select quadruple therapy with or without bismuth salts. However, all the treatment regimens often entail unpleasant side effects and lower compliance in children. In this review, the alternative and not yet commonly used therapeutic choices in children were also analyzed.
引用
收藏
页数:17
相关论文
共 85 条
  • [11] Flavonoids-Rich Plant Extracts Against Helicobacter pylori Infection as Prevention to Gastric Cancer
    de Araujo Rego, Renaly Ivyna
    Guedes Silvestre, Geovana Ferreira
    de Melo, Demis Ferreira
    Albino, Sonaly Lima
    Pimentel, Marcela Monteiro
    Costa Cruz, Sara Brito Silva
    Silva Wurzba, Sabrina Daniela
    Rodrigues, Wellington Francisco
    Goulart de Lima Damasceno, Bolivar Ponciano
    Cancado Castellano, Lucio Roberto
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [12] Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: A randomized clinical trial
    den Hoed, C. M.
    de Vries, A. C.
    Mensink, P. B. F.
    Dierikx, C. M.
    Suzuki, H.
    Capelle, L.
    van Dekken, H.
    Ouwendijk, R.
    Kuipers, E. J.
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY, 2011, 25 (04): : 207 - 213
  • [13] Bovine lactoferrin for Helicobacter pylori eradication:: an open, randomized, multicentre study
    Di Mario, F
    Aragona, G
    Dal Bó, N
    Cavallaro, L
    Marcon, V
    Olivieri, P
    Benedetti, E
    Orzéss, N
    Marin, R
    Tafner, G
    Chilovi, F
    DE Bastiani, R
    Fedrizzi, F
    Franceschi, M
    Salvat, MH
    Monica, F
    Piazzi, L
    Valiante, F
    Vecchiati, U
    Cavestro, GM
    Comparato, G
    Iori, V
    Maino, M
    Leandro, G
    Pilotto, A
    Rugge, M
    Franzè, A
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (08) : 1235 - 1240
  • [14] Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy
    Eto, Hiroyuki
    Suzuki, Sho
    Kusano, Chika
    Ikehara, Hisatomo
    Ichijima, Ryoji
    Ito, Hirotaka
    Kawabe, Koichi
    Kawamura, Masashi
    Yoda, Yoshioki
    Nakahara, Moriyasu
    Gotoda, Takuji
    [J]. HELICOBACTER, 2021, 26 (02)
  • [15] The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
    Fallone, Carlo A.
    Chiba, Naoki
    van Zanten, Sander Veldhuyzen
    Fischbach, Lori
    Gisbert, Javier P.
    Hunt, Richard H.
    Jones, Nicola L.
    Render, Craig
    Leontiadis, Grigorios I.
    Moayyedi, Paul
    Marshall, John K.
    [J]. GASTROENTEROLOGY, 2016, 151 (01) : 51 - +
  • [16] Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials
    Fang, Hao-Ran
    Zhang, Guo-Qiang
    Cheng, Jing-Yi
    Li, Zhong-Yue
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 2019, 178 (01) : 7 - 16
  • [17] Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis
    Feng, Jue-Rong
    Wang, Fan
    Qiu, Xiao
    McFarland, Lynne V.
    Chen, Peng-Fei
    Zhou, Rui
    Liu, Jing
    Zhao, Qiu
    Li, Jin
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (10) : 1199 - 1208
  • [18] Lactobacillus reuteri Strain Combination In Helicobacter pylori Infection A Randomized, Double- Blind, Placebo- Controlled Study
    Francavilla, Ruggiero
    Polimeno, Lorenzo
    Demichina, Antonella
    Maurogiovanni, Giovanni
    Principi, Beatrice
    Scaccianoce, Giuseppe
    Ierardi, Enzo
    Russo, Francesco
    Riezzo, Giuseppe
    Di Leo, Alfredo
    Cavallo, Luciano
    Francavilla, Antonio
    Versalovic, James
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2014, 48 (05) : 407 - 413
  • [19] Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin
    Furuta, T
    Shirai, N
    Takashima, M
    Xiao, F
    Hanai, H
    Nakagawa, K
    Sugimura, H
    Ohashi, K
    Ishizaki, T
    [J]. PHARMACOGENETICS, 2001, 11 (04): : 341 - 348
  • [20] Gaiani F., 2018, Biomed J Sci Tech Res, V4, P4160